Clinical Trial Update: A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible [NA]

View source ↗

Summary

A clinical trial from Xuzhou Medical University is evaluating anti-BCMA CAR-T therapy in newly diagnosed multiple myeloma patients who are transplant-ineligible…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-BCMA CAR-T therapy (BCMA-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Xuzhou Medical University | Conditions: Multiple Myeloma, Newly Diagnosed | NA | Status: NOT_YET_RECRUITING